0108908.01
Filed pursuant to
Rule 424(b)(3)
Registration Statement
No.: 33-97722
Prospectus Supplement No. 4 dated May 6, 1996
(To Prospectus dated December 7, 1995,
as supplemented on January 17, February 20 and April 2, 1996)
NEUROMEDICAL SYSTEMS, INC.
Common Stock
(par value $0.0001 per share)
On April 30, 1996, the Company announced results for
its first quarter ending March 31, 1996. Revenues for the first
quarter were $651,000, an increase of 29% from $504,000 for the
first quarter of 1995. The Company reported a net loss for the
first quarter of 1996 of $6,847,000, or $.24 net loss per share,
compared to a net loss of $3,860,000 or $.23 pro forma net loss
per share for the first quarter of 1995.
The increased net loss, compared to the first quarter of
1995, was due primarily to an increase in marketing and sales
expense and the expansion of the administrative and technical
infrastructure relating to the commercial launch of the PAPNET
Testing System in the United States following clearance by the
FDA on November 8, 1995.
The Company's efforts during the first quarter were focused
on building distribution for PAPNET testing in the United States.
During the quarter, PAPNET testing became available through 41
additional laboratories, bringing the total number of sites
offering the PAPNET test to 89 by the end of the quarter.
During the first quarter, the Company actually scanned pap
smears from 55 different laboratories in 25 states. The Company
increased its world-wide marketing and sales organization by
seven to a total of 41 persons during the quarter. The Company
expects to add an additional seven or eight marketing and sales
personnel during the second quarter of 1996.
